CVS HEALTH Corp: Form 10-Q for the period ended Mar 31, 2014
Filed with the SEC on May 2, 2014 and accepted by EDGAR at May 2, 2014, 17:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-01-01 to 2014-03-31 | $32.69bn | us-gaap:Revenues |
| Cost of revenue | 3 months2014-01-01 to 2014-03-31 | $26.75bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months2014-01-01 to 2014-03-31 | $5.94bn | us-gaap:GrossProfit |
| Operating income | 3 months2014-01-01 to 2014-03-31 | $2.02bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2014-01-01 to 2014-03-31 | $161.0m | us-gaap:InterestExpense |
| Income tax | 3 months2014-01-01 to 2014-03-31 | $737.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-01-01 to 2014-03-31 | $1.13bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2014-01-01 to 2014-03-31 | $0.95 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-01-01 to 2014-03-31 | $0.96 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2014-01-01 to 2014-03-31 | 1,190,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2014-01-01 to 2014-03-31 | $2.17bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2014-01-01 to 2014-03-31 | $388.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2014-01-01 to 2014-03-31 | $325.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 3 months2014-01-01 to 2014-03-31 | $801.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2014-03-31 | $2.77bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-03-31 | $24.46bn | us-gaap:AssetsCurrent |
| Total assets | At period end2014-03-31 | $72.82bn | us-gaap:Assets |
| Current liabilities | At period end2014-03-31 | $16.21bn | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2014-03-31 | $38.21bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000064803-14-000017. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.